NB-TAMSULOSIN CR DIN 02568721
Health Canada record
| Active ingredient(s) | TAMSULOSIN HYDROCHLORIDE 0.4 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G04CA02 TAMSULOSIN |
| Original market date | |
| Current status date | 29-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
NB Pharma Inc. — licence 3-002798, currently licensed, last inspection rating C (2025-12-05).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TAMSULOSIN HYDROCHLORIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02362406 | APO-TAMSULOSIN CR | APOTEX INC | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02545179 | AURO-TAMSULOSIN CR | AURO PHARMA INC | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02352419 | JAMP TAMSULOSIN | JAMP PHARMA CORPORATION | Capsule (Sustained-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02319217 | SANDOZ TAMSULOSIN | SANDOZ CANADA INCORPORATED | Capsule (Sustained-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02340208 | SANDOZ TAMSULOSIN CR | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02427117 | TAMSULOSIN CR | SANIS HEALTH INC | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02429667 | TAMSULOSIN CR | SIVEM PHARMACEUTICALS ULC | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02413612 | TAMSULOSIN CR | PRO DOC LIMITEE | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02368242 | TEVA-TAMSULOSIN CR | TEVA CANADA LIMITED | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Marketed |
| 02366231 | AVA-TAMSULOSIN CR | AVANSTRA INC | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Post Market |
| 02238123 | FLOMAX | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Capsule (Sustained-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Post Market |
| 02270102 | FLOMAX CR | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Tablet (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Post Market |
| 02298570 | MYLAN-TAMSULOSIN | MYLAN PHARMACEUTICALS ULC | Capsule (Extended-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Post Market |
| 02294885 | RAN-TAMSULOSIN | RANBAXY PHARMACEUTICALS CANADA INC. | Capsule (Sustained-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Post Market |
| 02294265 | RATIO-TAMSULOSIN | TEVA CANADA LIMITED | Capsule (Sustained-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Post Market |
| 02295121 | SANDOZ TAMSULOSIN | SANDOZ CANADA INCORPORATED | Capsule (Sustained-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Post Market |
| 02281392 | TEVA-TAMSULOSIN | TEVA CANADA LIMITED | Capsule (Sustained-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Post Market |
| 02333333 | UFLO | TRITON PHARMA INC | Capsule (Sustained-Release) | TAMSULOSIN HYDROCHLORIDE 0.4 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37634 | 2026-05-29 | Abbreviated New Drug Submission (ANDS) | Administrative: Licensing Agreement between two manufacturers |
International API supply for TAMSULOSIN HYDROCHLORIDE
20 valid EDQM Certificates of Suitability from 19 holders. 18 active FDA Drug Master Files.
Request a quote for NB-TAMSULOSIN CR